Introduction to 'A multitargeted approach: clinical advances in the treatment of solid tumours'.
暂无分享,去创建一个
[1] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[2] J. Desai,et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial , 2006, The Lancet.
[3] U. Gatzemeier,et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] R. Herbst,et al. A phase II trial of ZD6474 plus docetaxel in patients with previously treated NSCLC: Follow-up results. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] R. Govindan,et al. ZD6474 versus gefitinib in patients with advanced NSCLC: Final results from a two-part, double-blind, randomized phase II trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Motzer,et al. Sunitinib in patients with metastatic renal cell carcinoma. , 2006, JAMA.
[7] L. Rönnstrand,et al. The stem cell factor receptor/c-Kit as a drug target in cancer. , 2006, Current cancer drug targets.
[8] L. Ellis,et al. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. Kim,et al. Platelet-derived growth factor signaling and human cancer. , 2003, Journal of biochemistry and molecular biology.
[10] R. Figlin,et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.